共 50 条
- [31] CARDIOMYOPATHY AFTER TREATMENT FOR OSTEOSARCOMA - A CONTRIBUTION TO CARDIOTOXICITY OF ADRIAMYCIN KLINISCHE PADIATRIE, 1991, 203 (04): : 257 - 261
- [32] QUANTITATION OF THE EFFECTS OF ADRIAMYCIN (ADM) ON THE DISSEMINATION OF LEWIS LUNG-TUMOR CELLS PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1985, 26 (MAR): : 330 - 330
- [33] A COMPARATIVE-STUDY OF THE TOXICITIES OF FREE AND LIPOSOME-ASSOCIATED ADRIAMYCIN (ADM) PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1985, 26 (MAR): : 372 - 372
- [34] COMBINATION CHEMOTHERAPY WITH CISPLATINUM (CDDP) AND ADRIAMYCIN (ADM) IN POOR RISK SOLID TUMORS MEDICAL AND PEDIATRIC ONCOLOGY, 1987, 15 (06): : 347 - 347
- [35] VARIABLE RENAL PROTECTIVE RESPONSE TO ACE-INHIBITION IN ADRIAMYCIN (ADM) NEPHROSIS JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1994, 5 (03): : 959 - 959
- [37] DEVELOPMENT AND CHARACTERIZATION OF PEDIATRIC OSTEOSARCOMA (OS) XENOGRAFTS PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 430 - 430
- [39] CHEMOTHERAPY OF BRONCHOGENIC CARCINOMA WITH METHOTREXATE(MTX), ADRIAMYCIN(ADM), CYCLOPHOSPHAMIDE(CYT) AND CCNU PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1976, 17 (MAR): : 287 - 287
- [40] MONITORING OF ADRIAMYCIN (ADM) CARDIOTOXICITY (CT) BY SYSTOLIC-TIME INTERVALS (STI) PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1976, 17 (MAR): : 267 - 267